Search Results - "Noteboom J"

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Survey of 25 years' experience with (in-situ) rotor retaining-ring inspections.

Authors: Boxma, C. J. Noteboom, J. W.

Source: Insight: Non-Destructive Testing & Condition Monitoring. Sep2005, Vol. 47 Issue 9, p559-563. 5p. 11 Diagrams.

Anticipatory Modulation of Precision Grip Force With Variations in Limb Velocity of a Curvilinear Movement.

Authors: Weeks, Douglas L. Sherwood, David E. Noteboom, J. Timothy

Source: Journal of Motor Behavior. Mar2002, Vol. 34 Issue 1, p59. 8p.

Subjects: Extremities (Anatomy), Proprioceptors

The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy.

Authors: Melchior, S.W. Noteboom, J. Gillitzer, R. et al.

Source: BJU International. Aug2001, Vol. 88 Issue 3, p221-225. 5p. 2 Charts.

This result is not displayed to guests.
Login for full access.

Thrust Joint Manipulation Curricula in First-Professional Physical Therapy Education: 2012 Update.

Authors: NOTEBOOM, J. TIMOTHY LITTLE, CHRISTIAN BOISSONNAULT, WILLIAM

Source: Journal of Orthopaedic & Sports Physical Therapy. Jun2015, Vol. 45 Issue 6, p471-476.

Cardiovascular Assessment in the Orthopaedic Practice Setting.

Authors: Scherer, Susan A. Noteboom, J. Timothy Flynn, Timothy W.

Source: Journal of Orthopaedic & Sports Physical Therapy. Nov 2005: Vol. 35 Issue 11. p. 730-737-737.

Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer.

Authors: Ripping, T. M. Rammant, E. Witjes, J. A. et al.

Source: Health & Quality of Life Outcomes. 12/29/2022, Vol. 20 Issue 1, p1-12. 12p.

IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using ‘cracked’ adenoproducer cells.

Authors: Esandi, M C van Someren, G D Bout, A et al.

Source: Gene Therapy. Jun98, Vol. 5 Issue 6, p778. 11p.

Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene.

Authors: Esandi, M C van Someren, G D Vincent, A J P E et al.

Source: Gene Therapy. Apr97, Vol. 4 Issue 4, p280. 8p.

PO-1940 Online adaptive CBCT-guided VMAT radiotherapy using an Elekta Synergy CBCT-linac.

Authors: Groot Koerkamp, M. Bol, G. Kroon, P. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS1695-S1696. 2p.

PD-0900 Treating patients with a cardiac implant on a 1.5T MR-linac: a multi-centre experience.

Authors: Keesman, R. van der Bijl, E. Kerkmeijer, L. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS746-S747. 2p.

OC-0612 Recurrence characteristics in prostate cancer patients after (salvage) focal HDR brachytherapy.

Authors: Rasing, M. Peters, M. van Son, M. et al.

Source: Radiotherapy & Oncology. 2022 Supplement 1, Vol. 170, pS537-S538. 2p.

PO-1373 Targeted biopsies are redundant in mp-MRI and PSMA-PET proven radiorecurrent prostate cancer.

Authors: Peters, M. van Son, M. Rasing, M. et al.

Source: Radiotherapy & Oncology. 2021 Supplement 1, Vol. 161, pS1124-S1125. 2p.

1780TiP A phase II clinical study to assess efficacy of induction ipilimumab/nivolumab to spare the bladder in urothelial bladder cancer (INDI-BLADE).

Authors: Stockem, C.F. van Rhijn, B.W.G. Boellaard, T. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1351-S1351. 1p.

PT081 - Comparative effectiveness of salvage cryosurgery and high intensity focused ultrasound for radiorecurrent prostate cancer: A regression analysis.

Authors: Peters, M. Dewar, M. Hetou, K. et al.

Source: European Urology Supplements. Mar2018, Vol. 17 Issue 2, pe1838-e1839. 1p.

P024 - MRI-guided focal salvage High-Dose-Rate Brachytherapy (HDR-BT) for recurrent Prostate Cancer (PC) after primary radiotherapy.

Authors: Van Son, M.J. Peters, M. Dávila Fajardo, R. et al.

Source: European Urology Supplements. Nov2017, Vol. 16 Issue 10, pe2661-e2661. 1p.

OC-0056: FLAME: Influence of dose escalation to 95Gy for prostate cancer on urethra-related toxicity and QOL.

Authors: Van Loon, J. Van Vulpen, M. Pos, F. et al.

Source: Radiotherapy & Oncology. Apr2016 Supplement 1, Vol. 119, pS24-S24. 1p.

OC-0282: FLAME randomised trial: 95Gy MRI-boost vs 77Gy prostate radiotherapy: toxicity and quality of life.

Authors: Van Vulpen, M. Van Loon, J. Pos, F. et al.

Source: Radiotherapy & Oncology. Apr2016 Supplement 1, Vol. 119, pS132-S132. 1p.